Coronavirus LIVE Updates: In disappointing news on the vaccine front, pharmaceutical company AstraZeneca said it had "voluntarily paused" a randomised clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. The company, which is developing the drug alongside the University of Oxford, is a frontrunner in the global race for a Covid-19 vaccine. "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
It added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. "We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson added. It was not immediately clear where the patient was, or the nature and severity of their illness. Holds during clinical trials are not uncommon, but this is thought to be the first time it has happened for a Covid-19 vaccine trial. AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates. In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31. The vaccine, called AZD1222, uses a weakened version of a common cold causing adenovirus that has been engineered to code for the spike protein that the novel coronavirus uses to invade cells. After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected.
Read More
Sep 9, 2020 12:28 pm (IST)
Chennai Metro Rail services resumed in a graded manner in the Blue Line between Washermenpet to Airport from September 7 & green line between St. Thomas Mount & Puratchi Thalaivar Dr MG Ramachandran Central Metro today, September 9 from 7 am: Chennai Metro pic.twitter.com/xmJY3gKFwE
The COVID-19 case fatality rate has further dropped to 1.69 per cent. There are 8,97,394 active cases of COVID-19, which is 20.53 per cent of the total caseload in the country, the data stated.
Sep 9, 2020 12:23 pm (IST)
Union Health Minister Dr Harsh Vardhan attended the 73rd session of WHO Regional Committee for South East Asia, through video conferencing.
Delhi: Union Health Minister Dr Harsh Vardhan attended the 73rd session of WHO Regional Committee for South East Asia, through video conferencing. pic.twitter.com/YrRHXcizQG
Puducherry Covid Update | Five women and as many men succumbed to COVID-19 in Puducherry on Wednesday while 341 more people contracted the virus, pushing the tally of infections to 18,084. A release from Director of Health and Family Welfare S Mohan Kumar said 341 new cases were reported at the end oftesting of 2,560. The Director said nine out of the total deaths onWednesday occurred in Puducherry and remaining one wasreported from Karaikal region. Of the total 18,084 cases, 4,770 were active while 12,967patients recovered and discharged so far.
Sep 9, 2020 12:18 pm (IST)
Australia Not Worried About Trial Pause | Australia is not worried about AstraZeneca Plc's decision to put on hold its COVID-19 vaccine trial, its deputy chief medical officer said today, as daily cases nudged higher in the country's coronavirus hot spot. Australia's Deputy Chief Medical Officer Nick Coatsworth said the news does not mean the vaccine "is off the table". Coatsworth said Australia like many other governments has invested in several coronavirus vaccine candidates, "knowing not all of them will get through". Australia's coronavirus hot spot of Victoria on Wednesday, meanwhile, reported its biggest rise in daily cases now accounts for about 75% of Australia's 26,450 COVID-19 cases and 90% of its 781 deaths.
Sep 9, 2020 12:05 pm (IST)
Plasma Therapy May Be Safe, Effective in Children | Study Convalescent plasma therapy appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19, according to a small study. The research, published in the journal Pediatric Blood and Cancer, is the first report of convalescent plasma in children with life-threatening COVID-19.
Sep 9, 2020 11:49 am (IST)
Pak Reports 426 New COVID-19 Infections | Pakistan's number of coronavirus cases reached 299,659 today after 426 new infections were detected in the last 24 hours, the health ministry said. Nine patients died during the period, taking the number of fatalities to 6,359 across the country. As many as 544 people are in critical condition, the Ministry of National Health Services said. A total of 286,509 people have fully recovered from the disease. Sindh has reported 130,969 cases, Punjab 97,389, Khyber-Pakhtunkhwa 36,711, Islamabad 15,780, Balochistan 13,402, Gilgit-Baltistan 3,068 and Pakistan-occupied Kashmir 2,340 cases.
Sep 9, 2020 11:35 am (IST)
Dr Reddys Announce 'Redyx' in India | Dr Reddys Laboratories Ltd today announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name 'Redyx' in India. According to a press release from the drug maker, thelaunch is part of the licensing agreement with GileadSciences, Inc. (Gilead) that grants Dr Reddys the right toregister, manufacture and sell Remdesivir, a potentialtreatment for Covid-19, in 127 countries including India. Remdesivir is approved by Drug Controller General ofIndia (DCGI) for restricted emergency use in India for thetreatment of Covid-19 patients hospitalized with severesymptoms. "Dr Reddy's Redyx is available in strength of 100 mgvial," it said.
Sep 9, 2020 11:18 am (IST)
Odisha's Covid Update | Odisha reported 3,748 new COVID19 cases on September 8, taking the total number of positive cases in the state to 1,35,130 including 1,02,185 recoveries and 32,312 active cases: State Health Department
Sep 9, 2020 11:06 am (IST)
Agra Sees Rise in Covid Cases | All markets in Agra will now remain open except for the weekly off-day, as the Sunday lockdown has been lifted. The hospitality industry is now gearing up to welcome visitors from September 21 when the Taj Mahal and Agra Fort will be reopened. Senior-level schools have also been green signalled to start preparations to restart classes in a staggered manner. However, the surge in numbers of fresh cases of Covid-19 cases in the whole Agra region continued to remain alarming with the Taj city reporting 89 more cases in the past 24 hours.
Sep 9, 2020 10:51 am (IST)
Rajasthan Covid Case Update | 728 new COVID-19 positive cases and 7 deaths reported in Rajasthan. Total number of cases now at 94,854 including 15,761 active cases and 1,171 deaths, says State Health Department.
Sep 9, 2020 10:36 am (IST)
Delhi Police Designates Team to Maintain Covid Protocol | Delhi Police has said in view of spread of coronavirus in Delhi, each Police Station shall detail one dedicated team comprising of an upper subordinate & one lower subordinate to report to one location in their respective district to prosecute persons who violate protocols.
Sep 9, 2020 10:16 am (IST)
Covid Cases in Germany Rise to 253,474 | The number of confirmed coronavirus cases in Germany increased by 1,176 to 253,474, data from the Robert Koch Institute (RKI) for infectious diseases showed today. The reported death toll rose by nine to 9,338, the tally showed.
Sep 9, 2020 10:06 am (IST)
Covid Deaths in Mexico Climbs to 68,484 | Mexico reported 5,351 new confirmed cases Mexico reported 5,351 new confirmed cases of coronavirus infection and 703 additional fatalities yesterday, bringing its totals to 642,860 infections and 68,484 deaths, according to updated health ministry data. The government has said the real number of infected people is likely to be significantly higher than the confirmed cases.
Sep 9, 2020 9:54 am (IST)
More than 9 lakh COVID-19 deaths Across World | More than 9 lakh COVID-19 deaths were reported around the world. India again reports close to 90k new cases (89.7k) after 75.8k cases the previous day. Daily deaths in India have been more than 1,000 for 8 days in a row. Delhi reports 3.6k new cases, its highest in 75 days.
Sep 9, 2020 9:49 am (IST)
World-wide Update on Coronavirus Cases. USA Tops the number of coronavrus infections with India at number 2 with over 43 lakh cases..
Sep 9, 2020 9:47 am (IST)
Here's a state-wise breakdown of India's Covid case tally...
Sep 9, 2020 9:45 am (IST)
India's Covid Cases Cross 43 Lakh Mark | India's Covid-19 case tally crosses 43 lakh mark with a spike of 89,706 new cases and 1,115 deaths reported in the last 24 hours.
Sep 9, 2020 9:41 am (IST)
Brazil Eyeing Vaccine Rollout in Jan | Brazil's acting Health Minister Eduardo Pazuello said that a COVID-19 vaccine would be rolled out for all Brazilians in January 2021.Brazil has the third-worst outbreak of coronavirus globally with more than 4.1 million cases, passed this week by India for the second highest number of cases after the United States. More than 127,000 people have died from the disease, according to the official Health Ministry death toll.
Sep 9, 2020 9:28 am (IST)
England to Toughen up Restrictions | Tough new lockdown restrictions on social gatherings across the whole of England are to be announced on Wednesday as Prime Minister Boris Johnson tries to control a spike in COVID-19 infections. From September 14, groups of more than six people will be banned from meeting and fined if they fail to comply, Johnson will said. The number of cases in Britain has begun to rise sharply again in recent days. Although testing is more widespread and the number of people in hospital is well below the peak of the outbreak, ministers fear it is beginning to slip out of control.
Sep 9, 2020 9:20 am (IST)
Jordan Confirms 2 Covid-19 Cases in Syrian Refugee Camp | Jordanian authorities confirmed the first two cases of coronavirus in a refugee camp hosting Syrian refugees since the pandemic was first reported in the kingdom, the UN refugee agency said. The two Syrians who were transferred to an isolation site tested positive during random testing done by Jordanian health authorities in the Azraq camp, said Rula Amin, UNHCR spokeswoman for the Middle East and North Africa.
Sep 9, 2020 9:15 am (IST)
Israel Begins Night Curfew to Curb Covid Spike | Israel has begun a week-long campaign of night curfews and school closures in dozens of towns and neighbourhoods with high coronavirus counts, hoping to stem a spike in cases as its public-health chiefs were quarantined for exposure. Most of the 40 zones subject to the partial lockdowns are identified with Israeli Arabs or ultra-Orthodox Jews, minorities where crowding has led to spreading the pandemic. Israel, with a population of 9 million, has recorded 135,288 cases of the novel coronavirus and 1,031 deaths. The discovery that a worker at a Health Ministry project for combating the virus had contracted it prompted senior staff who had been exposed to him to self-isolate as a precaution.
Sep 9, 2020 9:05 am (IST)
A healthcare worker collects a swab from a passenger for a rapid antigen test upon his arrival at a railway station in Ahmedabad.
Sep 9, 2020 8:54 am (IST)
Canada Schools Reopen, Sees Spike in Covid Cases | Canada is seeing a worrying increase in the number of people infected with the coronavirus as schools across the country start to reopen, a top medical official said. Chief Public Health Officer Theresa Tam said an average of 545 new cases had been reported daily over the past week, up from about 300 in July. Several of the 10 provinces have started to reopen schools this week for in-person learning for the first time since March after investing millions in added protections. Quebec, which welcomed back pupils last month, has already reported a number of cases in schools.
Sep 9, 2020 8:50 am (IST)
A total of 5,18,04,677 samples tested up to 8th September 2020. Of these, 11,54,549 samples were tested yesterday: Indian Council of Medical Research (ICMR) pic.twitter.com/MdDvDizsa8
Remote Learning For New York State Colleges? | New York will require kindergarten through 12th grade schools to disclose the number of students and staff testing positive for COVID-19 and may force colleges with more than 100 cases to switch to remote learning, Governor Andrew Cuomo has said. Cuomo said the regulations would provide a check on the procedures put in place by colleges and give parents transparency about testing at elementary through high schools. Cuomo criticized the administration of New York University for not preventing a large gathering of students in nearby Washington Square Park in New York City on Saturday night, and listed several other colleges in the state that have had spikes in COVID-19 cases.
Sep 9, 2020 8:28 am (IST)
Feels Safe to Travel, say Commuters | Some more pictures as DMRC resumes operations on its Blue Line metro in Delhi today, scenes at the Rajiv Chowk metro station. A commuter called the resumption of train services a good decision and said COVID19 norms are being followed so it feels safe to travel.
Delhi: As part of stage-I of resumption of metro services, DMRC resumes operations on its Blue Line today; visuals from Rajiv Chowk metro station.
A commuter says, "It's a good decision to resume metro services; COVID19 norms being followed so it feels safe to travel" pic.twitter.com/thlhAM7R8b
French COVID-19 cases and deaths mount | The number of new confirmed cases of COVID-19 in France rose by 6,544 over the last 24 hours to give a total of 335,524 cases, the health ministry said, as the country battles to avert a second wave of the virus. The number of deaths also climbed by 39 over the last 24 hours to reach a total of 30,764. France has the world's seventh-highest COVID-19 death toll, and authorities are scrutinising the data to see what measures might be needed to help it cope with an expected second wave of the virus this winter.
The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing them into an active coronavirus patient.
Sep 9, 2020 8:12 am (IST)
54 patients recover from COVID19 in Nagaland, 25 more test positive, bringing infection tally to 4,245 in state and number of active cases to 496, said a Health department official.
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo
Meanwhile, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found that use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19. The 'open-label parallel-arm phase II multicentre randomised controlled trial' (PLACID Trial) was conducted across 39 public and private hospitals across India between April 22 to July 14 to investigate the effectiveness of convalescent plasma (CP) for the treatment of COVID-19, it said. The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection. A total of 464 participants (moderately ill COVID-19 patients admitted to hospitals) were enrolled for the study, which has not yet been peer-reviewed and has appeared on medRxiv, a preprint server.
The National Task Force for COVID-19, a committee formed by the ICMR to respond to the pandemic, has reviewed and approved this study, it said. The Clinical Management Protocols for COVID-19 issued by the Union Health Ministry on June 27 allowed use of convalescent plasma (Off label) for treating coronavirus-infected patients in moderate stage of the illness under "investigational therapies" This authorisation has been paralleled by questionable practices such as calls for donors on social media, and the sale of CP on the black market with exorbitant price tags in India, the study said.
Additionally, although CP is a safe therapeutic modality, plasmapheresis, plasma storage and NAb measurement are all resource-intensive processes, with a limited number of institutes in the country having the capacity to undertake these activities in a quality-assured manner. "The CP was not associated with reduction in mortality or progression to severe COVID-19," the study said, adding this trial has high generalisability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A prior measurement of neutralising antibody titres in donors and participants may further clarify the role of CP in management of COVID-19, it said.
The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given convalescent plasma along with best of standard care while 229 received only standard care, as per the study. Those in the intervention arm received two doses of 200 ml of CP, transfused 24 hours apart, in addition to the BSC (best standard of care). The two plasma units were collected preferably from different donors depending on the availability and ABO compatibility to increase chances of receiving CP with NAb, it said. "The PLACID trial results indicate that there was no difference in 28-day mortality or progression to severe disease among moderately ill COVID-19 patients treated with CP along with BSC compared to BSC alone," the study said.
The central implementation team at the ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report, the study stated. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in the ICMR had no role in it, it added.
Convalescent plasma (CP) as a passive source of neutralising antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. According to the study, only two randomised controlled trials on CP use in COVID-19 have been published, one from China and the other from the Netherlands.
Both were halted prematurely, the China study due to inadequate patient enrolment and the one from the Netherlands due to a need to redesign the trial based on interim findings. In both studies, no mortality benefit was noted, and the Dutch study raised uncertainties regarding pre-transfusion antibody-status of patients as a potential factor in identifying appropriate candidates for CP therapy.
This uncertainty in the published evidence is reflected in a recent systematic review, which remained undecided on both the safety and effectiveness of CP as a therapeutic option in hospitalized patients of COVID-19. Meanwhile, CP therapy has received regulatory approval for use in patients in different countries. This has resulted in its widespread adoption in real-world clinical practice, where it is being used to treat COVID-19 patients with a wide spectrum of disease severity.
"Given these uncertainties, we undertook the current study to determine the effectiveness of using CP in moderately ill COVID-19 patients admitted to hospitals across India in limiting progression to severe disease and determine the associated short-term adverse effects," the study said. All participants or their family members or legally authorised representatives were provided with information regarding the trial in a language they were comfortable with, and written informed consent was obtained prior to participant recruitment, it said.